Phio Pharmaceuticals Stock Price - PHIO

0.00 (0.0%)
Upgrade to Real-Time
Afterhours (Closed)
Best deals to access real time data!
Big Cap Pro
Monthly Subscription
for only
Small Cap Basic
Monthly Subscription
for only
Real-Time Alerts for Volume Breakouts, Highs and Lows for NYSE, NASDAQ, Amex, OTC Markets and OTCBB
Monthly Subscription
for only
VAT not included
Company Name Stock Ticker Symbol Market Type
Phio Pharmaceuticals Corporation PHIO NASDAQ Common Stock
  Price Change Change Percent Stock Price Low Price High Price Open Price Close Price Last Traded
-0.22 -9.48% 2.10 2.0201 2.39 2.39 2.32 20:00:00
Bid Price Ask Price Spread Spread % News
2.02 2.30 0.28 12.17% - -
Stock Trades Traded Volume VWAP Dollar Volume Average Volume 52 Week Range
343 69,865 $ 2.16 $ 150,641 319,745 0.097 - 10.85
Last Trade Time Type Quantity Stock Price Currency
16:00:00 2,637 $ 2.10 USD

Phio Pharmaceuticals Financials

Market Cap Shares in Issue Profit/Loss Earnings Per Share (EPS) PE Ratio Float
$ 3.90M 1.86M $ -7.36M -66.00 0.20 -
Short Interest Dividends Per Share Dividend Yield Ex-Div Date Insider B/S Insider % Owned
- $ - 0.00% - -

more financials information »

Phio Pharmaceuticals News

Loading Messages....

Latest PHIO Messages

{{bbMessage.M_Alias}} {{bbMessage.MSG_Date}} {{bbMessage.HowLongAgo}} {{bbMessage.MSG_ID}} {{bbMessage.MSG_Subject}}

Loading Messages....

No posts yet, be the first! No {{symbol}} Message Board. Create One! See More Posts on {{symbol}} Message Board See More Message Board Posts

Historical PHIO Price Data

Period † Open High Low VWAP Avg. Daily Vol Change %
1 Week2.102.501.972.2591,5700.000.0%
1 Month2.774.301.51012.62361,662-0.67-24.19%
3 Months0.194610.850.160.90507171,009,3961.91979.14%
6 Months0.26710.850.0970.5203003962,4061.83686.52%
1 Year0.4310.850.0970.4993351654,7901.67388.37%
3 Years0.3910.850.0970.4765033610,9301.71438.46%
5 Years0.3910.850.0970.4765033610,9301.71438.46%

Phio Pharmaceuticals Description

Phio Pharmaceuticals Corp is a US-based biotechnology company. It is principally engaged in developing immunooncology therapeutics based on its proprietary self-delivering RNAi platform and Samcyprone, a topical immunomodulator, which addresses significant unmet medical needs. The clinical development program of the company includes RXI-109, a sd-rxRNA for the treatment of dermal and ocular scarring, and Samcyprone, for the treatment of warts. The pipeline product of the company includes RXI-109, Immuno-oncology cell therapy, samcyprone, RXI-231, and RXI-185. The pipeline programs focus on dermatology, including cosmetic product development, ophthalmology, and cell-based cancer immunotherapy.

Your Recent History
Phio Pharm..
Register now to watch these stocks streaming on the ADVFN Monitor.

Monitor lets you view up to 110 of your favourite stocks at once and is completely free to use.